USPTO serial 79433400
COMPASS
Reviewed by CopyMark Law Group
Status 602
- Filing date
- Status date
- Registration date
- —
- Examiner
- LEIPZIG, MARC J
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with COMPASS?
CopyMark Law Group can help you respond to USPTO correspondence, keep a registration alive, or watch new filings against your mark.
Owner
Compass HealthAI Applications Inc.
CA
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Nutritional and nutraceutical supplements formulated to support ocular health, slow disease progression, and enhance retinal function, particularly for individuals diagnosed with late-stage macular disease or age-related macular degeneration (AMD). | ACTIVE | — |
| 009 | Downloadable software leveraging artificial intelligence (AI) algorithms for capturing, analyzing, and monitoring retinal images to assess disease progression, generate personalized treatment recommendations, and facilitate clinical decision-making; scientific and laboratory apparatus (not for direct clinical use) for collecting, interpreting, and managing research data related to ophthalmic treatments and disease models. | ACTIVE | — |
| 010 | Minimally invasive laser-based apparatus for the treatment and management of late-stage macular disease, age-related macular degeneration (AMD), and low central vision, designed to improve or maintain visual acuity and patient quality of life; medical diagnostic apparatus and instruments incorporating artificial intelligence for ophthalmic purposes; handheld and wearable medical diagnostic apparatus incorporating artificial intelligence for ophthalmic purposes; structural parts and fittings for the foregoing, for detecting, monitoring, and analyzing ocular conditions, namely, macular degeneration and other retinal disorders; interventional medical devices tailored to stabilize or restore sight in individuals suffering from low vision due to advanced retinal pathology. | ACTIVE | — |
| 040 | Custom manufacturing services for ophthalmic surgical instruments, ophthalmic laser apparatus for medical use, medical diagnostic apparatus, and structural parts and fittings for the foregoing, for others. | ACTIVE | — |
| 041 | Arranging and conducting seminars, webinars, workshops, and training programs for healthcare professionals and researchers on diagnosing, treating, and managing late-stage macular disease, age-related macular degeneration (AMD), and associated retinal conditions; publishing and distributing printed and electronic educational materials on best practices for ocular health maintenance, preventative eye care, and implementation of artificial intelligence (AI)-driven diagnostic and therapeutic approaches. | ACTIVE | — |
| 042 | Clinical and scientific research in the field of ophthalmology, focusing on the development, validation, and optimization of laser-based therapies, diagnostic devices, and minimally invasive interventions for retinal diseases; research and development (R&D) services aimed at advancing artificial intelligence (AI)-driven healthcare solutions, including predictive modeling, disease progression tracking, and outcome measurement in macular disease; providing online, non-downloadable software (SaaS/PaaS) with artificial intelligence (AI)-enabled analytics to support clinical decision-making, real-time patient monitoring, and health data management for improved vision care outcomes; technical consulting in the field of medical technology integration, including artificial intelligence (AI) algorithms, data analytics, and device interoperability for optimized patient care. | ACTIVE | — |
| 044 | Providing minimally invasive ocular treatments, including laser-based therapies, to improve or stabilize visual acuity in patients with late-stage macular disease; telehealth and remote patient monitoring services that utilize artificial intelligence (AI)-driven platforms to guide clinical evaluations, detect disease changes, and optimize treatment regimens for individuals with low central vision; medical consultancy to physicians, clinics, and healthcare institutions on the adoption and integration of laser therapy, artificial intelligence (AI)-empowered diagnostic tools, and evidence-based nutraceutical protocols for retinal disease management. | ACTIVE | — |
Prosecution history
| Date | Code | Event |
|---|---|---|
| Jun 8, 2026 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND |
| Jun 8, 2026 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Dec 11, 2025 | RFNT | REFUSAL PROCESSED BY IB |
| Nov 24, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Nov 24, 2025 | RFRR | REFUSAL PROCESSED BY MPU |
| Oct 4, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Oct 3, 2025 | CNRT | NON-FINAL ACTION WRITTEN |
| Sep 30, 2025 | DOCK | ASSIGNED TO EXAMINER |
| Sep 29, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED |
| Sep 29, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Sep 25, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB |